We are developing a world-class platform of #radiopharmaceutical and #nuclearmedicine products for both diagnostic and #therapeutic uses. ASX: $RAD
Australia
Joined July 2021
- Tweets486
- Following709
- Followers1.2K
- Likes1K
We have successfully completed an End-of-Phase 2 meeting with the US FDA regarding RAD 101: buff.ly/C93GpVX
The constructive FDA interaction provides a clear framework for our RAD101 pivotal clinical development plan.
Data from an interim analysis of our Phase 2b imaging clinical trial of RAD101 in participants with suspected recurrent brain metastases from solid tumors has been selected for an oral presentation at the Annual Meeting of the Society of Neuro-Oncology: buff.ly/ufMaAvj
We've announced positive data from the Phase 1 imaging trial designed to evaluate the safety, biodistribution & dosimetry of RAD301 in healthy volunteers & subjects with PDAC: buff.ly/PMtu7zk
The data demonstrated a favorable safety profile in all evaluable participants.
The first patient has been dosed in the second cohort of our First-In-Human Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors, following positive recommendation from the Safety and Monitoring Committee: buff.ly/qDMqg3d
We have received a positive recommendation from the Data Safety and Monitoring
Committee to advance RAD202 to the next dose level of 180mCi in the Phase 1 ‘HEAT’ clinical trial in patients with HER2-positive advanced solid tumors: buff.ly/oOe4Acq
We have scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1st, 2026, to align on the design of a pivotal Phase 3 trial to evaluate RAD101 in patients with suspected recurrence of brain metastases following radiotherapy: buff.ly/9pQZjJ2
Today we announced our financial results for the quarter ended June 30, 2026, and provided a corporate update: buff.ly/le2Ey3R
We continue to make meaningful progress across our portfolio as we advance a diverse pipeline of targeted radiopharmaceutical candidates.
We are pleased to share that we have received firm commitments for an approximately A$12.5 million institutional capital raising: buff.ly/hnXSF3A
We have also launched a Share Purchase Plan for existing eligible shareholders to raise up to a further A$6m.
We're pleased to share updated clinical results from the first 2 patients in the 3rd cohort of RAD204: buff.ly/jL7hyE8
Both patients remain on treatment, and initial clinical observations from the ongoing study support the potential of repeated administration of RAD204.
Today we announced positive data from all 30 evaluable patients in the Phase 2b trial of RAD101 for the diagnosis of brain metastases: buff.ly/ccdK5ZY
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.
New data from the ongoing Phase 1 HEAT trial evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented at the American Association for Cancer Research Annual Meeting, being held this week in San Diego: buff.ly/y7w2maD
We're pleased to share that the final patient has been dosed in the US Phase 2b imaging trial evaluating RAD 101 in individuals with confirmed recurrent brain metastases from solid tumors of different origin: buff.ly/q6HiIJC
We have received a positive recommendation from the DSMC to advance our clinical-stage radiotherapeutic asset, RAD202, to the next dose level of in the Phase 1 ‘HEAT’ clinical trial in patients with HER2-positive advanced solid tumors: buff.ly/BmgsHVN
Today we announced the signing of a supply agreement in which Siemens Healthineers will radiolabel and distribute RAD101 with Fluorine-18: buff.ly/vGzKQNo
Today we shared that the first patient has been dosed in our first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 being evaluated in advanced prostate cancer: buff.ly/LOzOxdn
We're pleased to share the second interim data from 20 patients in our U.S. Phase 2b clinical imaging trial of RAD 101 in brain metastases: buff.ly/AIAt4Fn
The analysis showed that 90% of the patients dosed with RAD101 achieved the primary endpoint.
We are hosting a webinar on March 25 at 9:00 am AEDT (Sydney, Melbourne) / Tuesday, March 24 at 6:00 pm EST (U.S.) to discuss the second interim data.
Register at: buff.ly/e74t4BE
We're pleased to share that CEO & Managing Director Riccardo Canevari will present at the @NWRComms Virtual Healthcare Conference on Wednesday, 25 March, at 8:30am AEDT.
Investors, shareholders, and interested parties are invited to register at: buff.ly/xWH8yac
The first patient has been dosed in our First-In-Human Phase 1/2a trial of 177Lu-Betabart: buff.ly/EUWBDyo
The dose escalation & expansion trial is designed to evaluate its safety, biodistribution and radiation dosimetry, along with preliminary anti-tumor activity.
We are pleased to share an update from Brookline Capital Markets on $RAD following a fireside chat with CEO Riccardo Canevari.
Brookline maintains its Buy recommendation for the Company and a target price of $13 (NASDAQ)/$0.06 (ASX).
